文献速递乳腺癌放疗

保乳术后单纯辅助放疗是50岁以上低危早期乳腺癌的有效选择:加拿大省级数据库人群队列研究

Adjuvant radiotherapy alone, an effective treatment option for early-stage low- risk breast cancer in women over 50: results from a population based cohort study using a Canadian provincial database.
PubMed 文献 · Radiother Oncol · 2025-09-29

该研究基于加拿大省级数据库纳入2810例50-80岁T1N0 ER阳性Her-2阴性早期乳腺癌患者,保乳术后接受单纯放疗、单纯内分泌治疗、放疗联合内分泌治疗或仅保乳手术。中位随访73个月,各辅助治疗组与仅保乳手术相比无复发生存和乳腺癌特异性生存无统计学显著差异,但单纯放疗、单纯内分泌治疗及联合治疗均显著改善总生存。研究支持单纯辅助放疗可作为50岁以上低危早期乳腺癌患者内分泌联合放疗的可行替代方案。

要点

  • 50岁以上低危早期乳腺癌保乳术后单纯辅助放疗的总生存显著优于仅保乳手术。
  • 单纯放疗与单纯内分泌治疗、放疗联合内分泌治疗相比,无复发生存和乳腺癌特异性生存无统计学显著差异。
  • 仅22.2%患者完成5年内分泌治疗,提示内分泌治疗依从性存在问题。

核心结论

  • 保乳术后单纯辅助放疗、单纯内分泌治疗及放疗联合内分泌治疗与仅保乳手术相比,无复发生存和乳腺癌特异性生存无统计学显著差异。
  • 单纯辅助放疗、单纯内分泌治疗及放疗联合内分泌治疗均较仅保乳手术显著改善总生存。
  • 研究支持单纯辅助放疗可作为50岁以上低危早期乳腺癌患者内分泌联合放疗的可行替代方案。

研究设计与样本

  • 基于加拿大省级数据库的人群队列研究,纳入2010至2015年50-80岁T1N0 ER阳性Her-2阴性早期乳腺癌保乳术后患者2810例。
  • 辅助治疗分组包括仅保乳手术216例(8%)、单纯放疗803例(29%)、单纯内分泌治疗274例(10%)、放疗联合内分泌治疗1517例(54%)。
  • 中位随访73个月(四分位距Q1,Q3:55.0,91.6),主要结局为无复发生存、总生存和乳腺癌特异性生存。

主要发现

  • 与仅保乳手术相比,各辅助治疗组无复发生存和乳腺癌特异性生存无统计学显著差异。
  • 与仅保乳手术相比,总生存风险比:单纯放疗0.66(95%CI:0.45-0.97),单纯内分泌治疗0.55(95%CI:0.35-0.87),放疗联合内分泌治疗0.48(95%CI:0.33-0.70)。
  • 总生存的决定因素包括年龄、肿瘤分级、合并症和辅助治疗。
  • 398例患者(22.2%)完成5年内分泌治疗。

临床怎么用

  • 对50岁以上低危早期乳腺癌患者,保乳术后单纯辅助放疗可作为内分泌联合放疗的可行替代选择。
  • 临床决策需结合年龄、肿瘤分级、合并症及内分泌治疗依从性综合评估。

局限性

  • 原文未报告该研究的局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast conserving surgery (BCS) is the primary treatment for early-stage breast cancer(EBC). Typically, adjuvant endocrine therapy (ET) and radiation therapy (RT) are standard treatments offered for EBC. However, non-compliance and toxicity remain as issues with HT and many patients choose adjuvant RT alone. The benefit of adjuvant RT alone in women with low-risk EBC remains unclear. It is hypothesized that adjuvant RT-alone can improve outcomes in low-risk EBC patients, similar to ET alone or RT + ET combination. METHODS: This population-based study identified women aged 50-80 with T1, N0, Estrogen receptor positive (ER + ve), human epidermal growth receptor-2 negative(Her-2/neu-ve) EBC treated with BCS, followed by adjuvant treatments (RT-alone, ET-alone, or RT + ET combination) from 2010 to 2015. Primary outcomes were recurrence free survival (RFS), overall survival (OS), and breast cancer specific survival (BCSS). RESULTS: 2810 patients were identified. Median follow-up was 73 months(Interquartile Q1,Q3:55.0,91.6). Adjuvant treatments were: BCS only 216 (8 %), RT alone 803 (29 %), ET alone 274 (10 %), and RT + ET combination 1517 (54 %). 398 patients (22.2 %) completed 5-years of ET. Compared to BCS alone, there was no statistically significant difference between treatment groups for RFS and BCSS. There were significant difference among the treatment groups for OS compared to BCS alone: Hazard ratio (HR) 0.66 (95 % confidence interval (CI): 0.45 - 0.97) for RT alone, 0.55 (95 % CI: 0.35 - 0.87) for ET alone, and 0.48 (95 % CI: 0.33 - 0.70) for RT + ET combination. Determinants of OS were age, tumor grade, comorbidities, and adjuvant therapy. CONCLUSIONS: Our population-based cohort study showed that there was no statistically significant difference in RFS and BCSS among various adjuvant treatments versus BCS alone. However, RT alone, ET alone and RT + ET combination resulted in a statistically significant improvement in OS compared to BCS alone. Our findings support RT alone can be a viable alternative to ET + RT combination for women over 50 with low-risk EBC. Ongoing studies like EUROPA, REaCT trial and EPOPE will provide more insight into the role of RT alone as a definite treatment option.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Joseph K, Ademola A, Zebak J, et al. Adjuvant radiotherapy alone, an effective treatment option for early-stage low- risk breast cancer in women over 50: results from a population based cohort study using a Canadian provincial database. Radiother Oncol. 2025. PMID: 41033355. doi:10.1016/j.radonc.2025.111175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。